A

year ago, when Merck’s (MRK) latest treatment for Alzheimer’s disease came up a dud, the company saw a silver lining. By targeting patients with early forms of the disease, yet to show major symptoms, researchers saw a winning pathway for the drug, which looked like it was hitting its molecular targets.

They were wrong.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.